ReviewNPJ Parkinson's disease2025
New perspectives on molecular mechanisms underlying exercise-induced benefits in Parkinson's disease.
Review in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Myokine Signaling in Sarcopenia-Associated Chronic Musculoskeletal Pain: A Systematic Review of Inflammatory Mechanisms.International journal of molecular sciences · 2026Pooled it
- Physical activity promotes clinical benefits beyond dopaminergic preservation in Parkinson's disease: a longitudinal analysis of the PPMI cohort.Neurological research and practice · 2026Article
- Exercise, exerkines, and muscle-brain crosstalk in Parkinson's disease.Neuroprotection (Chichester, England) · 2026Review
- LINC-EPS Protects Against Neurodegeneration by Driving a PGC-1α-Mediated Anti-Ferroptosis Program in Parkinson's Disease.International journal of biological sciences · 2026Article
- Glial-Dopamine crosstalk: Astrocytic and microglial gatekeepers of neuroinflammation, plasticity, and motivation.AIMS neuroscience · 2026Review
- Exercise modulation of BDNF/TrkB signaling in Parkinson's disease: an evidence-calibrated review of neuroprotective mechanisms, biomarker limitations, and translational gaps.Frontiers in neurology · 2026Review
- Exercise suppresses apoptosis for alleviating Parkinson's disease: effects on pathophysiological molecular pathways.Frontiers in aging neuroscience · 2026Review
- Parkinson's Disease and Frailty: A Two-Way Link Across Aging.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Exercise offers neuroprotective benefits in Parkinson's disease (PD) by enhancing neurotrophic factors (e.g., BDNF, GDNF), improving mitochondrial function, reducing inflammation, and promoting autophagy. Irisin, a muscle-derived cytokine, links exercise to neuronal health by regulating mitochondria and mitigating oxidative stress. Notably, irisin may serve as a therapeutic target for patients unable to exercise. Thus, exercise is a promising non-pharmacological intervention warranting further research for novel PD therapies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.